ATE557002T1 - Verbindungen mit calcimimetischer wirkung - Google Patents
Verbindungen mit calcimimetischer wirkungInfo
- Publication number
- ATE557002T1 ATE557002T1 AT01938319T AT01938319T ATE557002T1 AT E557002 T1 ATE557002 T1 AT E557002T1 AT 01938319 T AT01938319 T AT 01938319T AT 01938319 T AT01938319 T AT 01938319T AT E557002 T1 ATE557002 T1 AT E557002T1
- Authority
- AT
- Austria
- Prior art keywords
- group
- chr5
- alkyl
- aryl
- hydrogen atom
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 102100035650 Extracellular calcium-sensing receptor Human genes 0.000 abstract 2
- 101710159793 Extracellular calcium-sensing receptor Proteins 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004422 alkyl sulphonamide group Chemical group 0.000 abstract 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0006619A FR2809396B1 (fr) | 2000-05-24 | 2000-05-24 | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
| PCT/FR2001/001599 WO2001090069A1 (fr) | 2000-05-24 | 2001-05-23 | Composes possedant une activite calcimimetique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE557002T1 true ATE557002T1 (de) | 2012-05-15 |
Family
ID=8850558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01938319T ATE557002T1 (de) | 2000-05-24 | 2001-05-23 | Verbindungen mit calcimimetischer wirkung |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7084167B2 (de) |
| EP (1) | EP1284963B1 (de) |
| JP (1) | JP2003534324A (de) |
| AT (1) | ATE557002T1 (de) |
| AU (1) | AU2001264012A1 (de) |
| FR (1) | FR2809396B1 (de) |
| WO (1) | WO2001090069A1 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6908935B2 (en) | 2002-05-23 | 2005-06-21 | Amgen Inc. | Calcium receptor modulating agents |
| US7176322B2 (en) | 2002-05-23 | 2007-02-13 | Amgen Inc. | Calcium receptor modulating agents |
| DK3395338T3 (da) | 2003-09-12 | 2019-07-22 | Amgen Inc | Hurtigt opløsende formulering af cinacalcet-hcl |
| WO2005065050A2 (ja) * | 2003-12-25 | 2005-07-21 | Asahi Kasei Pharma Corporation | 2環化合物 |
| JP4629036B2 (ja) | 2004-05-28 | 2011-02-09 | 田辺三菱製薬株式会社 | アリールアルキルアミン化合物及びその製法 |
| US7361789B1 (en) | 2004-07-28 | 2008-04-22 | Amgen Inc. | Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis |
| FR2885129B1 (fr) * | 2005-04-29 | 2007-06-15 | Proskelia Sas | Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation. |
| AU2006316705B2 (en) * | 2005-11-25 | 2011-09-29 | Galapagos Sas | Urea derivatives useful as calcium receptor modulators |
| KR20080110681A (ko) * | 2006-04-20 | 2008-12-18 | 암겐 인코포레이티드 | 안정적 에멀젼 조제물 |
| JP5470653B2 (ja) * | 2006-10-26 | 2014-04-16 | アムジエン・インコーポレーテツド | カルシウム受容体調節剤 |
| WO2008121386A2 (en) | 2007-03-30 | 2008-10-09 | Amgen Inc. | Calcimimetic compounds for use in the treatment of bowel disorders |
| AU2008311974B2 (en) * | 2007-10-15 | 2013-11-21 | Amgen Inc. | Calcium receptor modulating agents |
| KR101700152B1 (ko) * | 2008-10-03 | 2017-01-26 | 이에이 파마 가부시키가이샤 | CaSR 효능제 |
| WO2010042642A1 (en) * | 2008-10-08 | 2010-04-15 | Amgen Inc. | Calcium receptor modulating agents |
| WO2010104882A1 (en) | 2009-03-10 | 2010-09-16 | Amgen Inc. | Methods of modulating sperm motility |
| CA2762137A1 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| EP2435400A2 (de) | 2009-05-27 | 2012-04-04 | Leo Pharma A/S | Neue, den calcium sensing receptor modulierende verbindungen und deren pharmazeutische verwendung |
| CN102958907A (zh) | 2010-06-30 | 2013-03-06 | 利奥制药有限公司 | 钙敏感受体激动化合物的新多晶型 |
| WO2012000499A1 (en) | 2010-06-30 | 2012-01-05 | Leo Pharma A/S | New polymorphic form of a calcimimetic compound |
| EP2643298A1 (de) | 2010-11-26 | 2013-10-02 | Leo Pharma A/S | Substituierte cyclopentylazine als casr-aktive verbindungen |
| WO2012069419A1 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| WO2012069421A1 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| US20130244995A1 (en) | 2010-11-26 | 2013-09-19 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| FR2969150B1 (fr) | 2010-12-20 | 2013-07-26 | Centre Nat Rech Scient | Nouvelles molecules indoliques demontrant des activites antibacteriennes dans une variete de bacteries a gram-negatif et positif dont des bacteries multidrogues-resistantes |
| CA2828415A1 (en) | 2011-03-10 | 2012-09-13 | Lupin Limited | Substituted morpholines as modulators for the calcium sensing receptor |
| WO2012127388A1 (en) | 2011-03-18 | 2012-09-27 | Lupin Limited | Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators |
| SMT201900506T1 (it) | 2012-02-24 | 2019-11-13 | Lupin Ltd | Composti cromanici sostituiti come modulatori dei recettori sensibili al calcio |
| WO2013136288A1 (en) | 2012-03-16 | 2013-09-19 | Lupin Limited | Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators |
| EP2888225A1 (de) | 2012-08-27 | 2015-07-01 | Lupin Limited | Arylalkylaminverbindungen als kalziumerfassende rezeptormodulatoren |
| GB201217330D0 (en) | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
| TW201602062A (zh) | 2013-08-12 | 2016-01-16 | 魯賓有限公司 | 取代聯苯基化合物作為鈣敏感受體調節劑 |
| AU2014313835A1 (en) * | 2013-08-28 | 2016-03-03 | Lupin Atlantis Holdings Sa | Substituted naphthalene compounds as calcium sensing receptor modulators |
| WO2015162538A1 (en) | 2014-04-21 | 2015-10-29 | Lupin Limited | Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease |
| WO2017037616A1 (en) | 2015-08-31 | 2017-03-09 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
| AU2020415502A1 (en) | 2019-12-27 | 2022-07-14 | Lupin Limited | Pharmaceutical composition of CaSR modulators and methods and uses thereof |
| LT4090654T (lt) | 2020-01-17 | 2025-11-10 | Chromanų junginių gamybos būdai, procesai ir tarpiniai produktai | |
| JP2024520832A (ja) | 2021-06-08 | 2024-05-24 | エンセオジェニックス バイオサイエンシズ, インコーポレイテッド | セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤 |
| AU2022425198A1 (en) | 2021-12-27 | 2024-07-18 | Atai Therapeutics, Inc. | Aminotetraline activators of serotonin receptors |
| WO2024192150A2 (en) * | 2023-03-16 | 2024-09-19 | Atai Therapeutics Inc. | 3-alkylamine indole activators of serotonin receptors |
| WO2024229149A1 (en) | 2023-05-01 | 2024-11-07 | Atai Therapeutics Inc. | Compositions and methods for treatment of diseases and disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3906099A (en) * | 1972-06-08 | 1975-09-16 | Warner Lambert Co | 1,2,3,4-Tetra hydro-3-aminomethylisoquinolines in the treatment of mental depression |
| ES2002416A6 (es) * | 1986-10-14 | 1988-08-01 | Consejo Superior Investigacion | Procedimiento para la obtencion de derivados acetilenicos y alenicos de 2-aminometil-(1-metilindoles) |
| ES2010406A6 (es) * | 1989-02-16 | 1989-11-01 | Consejo Superior Investigacion | Procedimiento para la obtencion de derivados acetilenicos y alenicos de 2-aminometil-(1-metil-indoles). |
| ATE312347T1 (de) * | 1991-08-23 | 2005-12-15 | Nps Pharma Inc | Screening-verfahren für kalzium-rezeptor aktive verbindungen |
| CN1312116C (zh) * | 1994-10-21 | 2007-04-25 | Nps药物有限公司 | 钙受体活性化合物 |
| WO1996023789A1 (en) * | 1995-02-03 | 1996-08-08 | Sankyo Company, Limited | Hexahydropyrazinoquinoline derivatives |
| DE69614870D1 (de) * | 1995-10-16 | 2001-10-04 | Procter & Gamble | Haarpflegeshampoo |
| JP2002527414A (ja) * | 1998-10-14 | 2002-08-27 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 1,2−ジ置換シクロプロパン |
| CN1161340C (zh) * | 1998-11-30 | 2004-08-11 | 先灵公司 | 为玻连蛋白受体拮抗剂的苯并咪唑化合物 |
| CN1334801A (zh) | 1998-12-16 | 2002-02-06 | 拜尔公司 | 作为整联蛋白拮抗剂的新的联苯基和类似联苯基的化合物 |
| FR2798845B1 (fr) * | 1999-09-29 | 2001-11-23 | Oreal | Composition de lavage des matieres keratiniques, a base d'un agent tensio-actif detergent, d'un polyorganosiloxane et d'un terpolymere acrylique |
| FR2800735B1 (fr) | 1999-11-09 | 2002-02-01 | Centre Nat Rech Scient | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation |
-
2000
- 2000-05-24 FR FR0006619A patent/FR2809396B1/fr not_active Expired - Fee Related
-
2001
- 2001-05-23 AT AT01938319T patent/ATE557002T1/de active
- 2001-05-23 US US10/296,288 patent/US7084167B2/en not_active Expired - Fee Related
- 2001-05-23 EP EP01938319A patent/EP1284963B1/de not_active Expired - Lifetime
- 2001-05-23 WO PCT/FR2001/001599 patent/WO2001090069A1/fr not_active Ceased
- 2001-05-23 AU AU2001264012A patent/AU2001264012A1/en not_active Abandoned
- 2001-05-23 JP JP2001586258A patent/JP2003534324A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20030199497A1 (en) | 2003-10-23 |
| EP1284963B1 (de) | 2012-05-09 |
| FR2809396A1 (fr) | 2001-11-30 |
| WO2001090069B1 (fr) | 2002-04-11 |
| WO2001090069A1 (fr) | 2001-11-29 |
| AU2001264012A1 (en) | 2001-12-03 |
| FR2809396B1 (fr) | 2005-10-14 |
| US7084167B2 (en) | 2006-08-01 |
| EP1284963A1 (de) | 2003-02-26 |
| JP2003534324A (ja) | 2003-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE557002T1 (de) | Verbindungen mit calcimimetischer wirkung | |
| ATE268752T1 (de) | Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung | |
| AR036032A1 (es) | Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif | |
| AR012593A1 (es) | Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento | |
| TNSN03045A1 (en) | QUINAZOLINES AS MMP-13 INHIBITORS | |
| HUP0102793A2 (hu) | Agydaganat kezelésére szolgáló kinazolinok és ezeket tartalmazó gyógyszerkészítmények | |
| AR017021A1 (es) | Acido 2-hidroxiacetico | |
| SE9904176D0 (sv) | New use | |
| BR0317294A (pt) | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários | |
| NO20052914L (no) | Terapeutiske forbindelser | |
| CY1107080T1 (el) | Υποκατεστημενες ινδολο-βασεις του mannich | |
| AR023060A1 (es) | Uso de un compuesto que es un derivado de 2-ureido-1,3-tiazol, nuevos derivados de 2-ureido-1,3-tiazol, procedimientos para prepararlos y composicionesfarmaceuticas que los comprenden | |
| HUP0400206A2 (hu) | Metalloproteináz inhibitor hatású imidazolidin-dion-származékok, ezek alkalmazása gyógyszerkészítmények előállítására és ezeket tartalmazó gyógyszerkészítmények | |
| ATE383339T1 (de) | Amin-derivate zur behandlung von apoptosis | |
| ES2133163T3 (es) | Esteres (o tioesteres) del acido n-acilsulfamico y esteres (o tioesteres) del acido n-sulfonilcarbamico como agentes hipercolesterolemicos. | |
| HUP0101999A2 (hu) | 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása | |
| SE9903760D0 (sv) | New compounds | |
| SE0104334D0 (sv) | Therapeutic agents | |
| DE502004005033D1 (de) | Substituierte 2-aminotetraline zur behandlung von depressionen | |
| HUP0401638A2 (hu) | Daganatellenes hatású tiofén- és tiazolszulfonamid származékok, valamint ezeket tartalmazó gyógyászati készítmények | |
| DZ1694A1 (fr) | "n-(2-Aminoethyl)-benzothialozones". | |
| AU8799201A (en) | Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases | |
| AR035451A1 (es) | Derivados de beta-carbolina, su uso para la fabricacion de un medicamento para el tratamiento de la depresion, ansiedad y desordenes bipolares, una composicion farmaceutica y una combinacion. | |
| ATE409038T1 (de) | Verwendung eines hydroximinsäure-halogenid- derivats bei der behandlung von neurodegenerativen erkrankungen | |
| RU2396264C2 (ru) | Производные хромана и их применение в качестве лигандов 5-нт рецептора |